![[Weekly funding roundup May 24-30] Capital inflow continues to remain steady](https://images.yourstory.com/cs/2/220356402d6d11e9aa979329348d4c3e/Weekly-funding-1741961216560.jpg)
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.Read more...
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.
